Switch theme
Sign up to access all valuation multiples
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical, and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include drug discovery, drug development, pharmaceutical product development, and laboratory testing in the USA and Canada; and the PRC segment includes the same services provided in the People's Republic of China. The company generates a majority of its revenue from USA followed by the PRC and the rest of the world.
2018
1.8K+
LTM Revenue $2.0B
LTM EBITDA n/a
$414M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Frontage Laboratories has a last 12-month revenue of $2.0B and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Frontage Laboratories achieved revenue of $33.4M and an EBITDA of $7.4M.
Frontage Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Frontage Laboratories valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $32.2M | $33.4M | XXX | XXX | XXX |
| Gross Profit | $8.6M | $11.5M | XXX | XXX | XXX |
| Gross Margin | 27% | 34% | XXX | XXX | XXX |
| EBITDA | $9.0M | $7.4M | XXX | XXX | XXX |
| EBITDA Margin | 28% | 22% | XXX | XXX | XXX |
| Net Profit | $2.4M | $3.3M | XXX | XXX | XXX |
| Net Margin | 7% | 10% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Frontage Laboratories's stock price is HKD 1 (or $0).
Frontage Laboratories has current market cap of HKD 2.4B (or $304M), and EV of HKD 3.2B (or $414M).
See Frontage Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $414M | $304M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Frontage Laboratories has market cap of $304M and EV of $414M.
Frontage Laboratories's trades at 1.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Frontage Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Frontage Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $414M | XXX | XXX | XXX |
| EV/Revenue | 12.4x | XXX | XXX | XXX |
| EV/EBITDA | 56.3x | XXX | XXX | XXX |
| P/E | 219.1x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 173.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFrontage Laboratories's NTM/LTM revenue growth is 9%
Frontage Laboratories's revenue per employee for the last fiscal year averaged $19K, while opex per employee averaged $4K for the same period.
Over next 12 months, Frontage Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Frontage Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Frontage Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 31% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $19K | XXX | XXX | XXX | XXX |
| Opex per Employee | $4K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 22% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Frontage Laboratories acquired XXX companies to date.
Last acquisition by Frontage Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Frontage Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Frontage Laboratories founded? | Frontage Laboratories was founded in 2018. |
| Where is Frontage Laboratories headquartered? | Frontage Laboratories is headquartered in Hong Kong. |
| How many employees does Frontage Laboratories have? | As of today, Frontage Laboratories has 1.8K+ employees. |
| Is Frontage Laboratories publicy listed? | Yes, Frontage Laboratories is a public company listed on HKG. |
| What is the stock symbol of Frontage Laboratories? | Frontage Laboratories trades under 01521 ticker. |
| When did Frontage Laboratories go public? | Frontage Laboratories went public in 2019. |
| Who are competitors of Frontage Laboratories? | Similar companies to Frontage Laboratories include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Frontage Laboratories? | Frontage Laboratories's current market cap is $304M |
| What is the current revenue of Frontage Laboratories? | Frontage Laboratories's last 12-month revenue is $2.0B. |
| What is the current EV/Revenue multiple of Frontage Laboratories? | Current revenue multiple of Frontage Laboratories is 1.6x. |
| What is the current revenue growth of Frontage Laboratories? | Frontage Laboratories revenue growth between 2023 and 2024 was 4%. |
| Is Frontage Laboratories profitable? | Yes, Frontage Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
